Condition

Recurrent Non-small Cell Lung Cancer

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 88 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials88
Recruiting1
Common interventions25
Lead sponsors shown15
Advertisement

Clinical trials

60 shown
A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung CancerNCT02889666 · 2008-01-01
RECRUITING
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)NCT04623775 · 2021-02-17
COMPLETED
Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung CancerNCT02845856 · 2016-07-01
COMPLETED
Safety and Efficacy of Vitamin C Infusion in Combination With Local mEHT to Treat Non Small Cell Lung CancerNCT02655913 · 2015-12-01
COMPLETED
Hypofractionated Boost Before Chemoradiation for Patients With Stage II-III Non-small Cell Lung Cancer Unsuitable for SurgeryNCT02262325 · 2015-06-08
COMPLETED
Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung CancerNCT02132884 · 2015-03-01
TERMINATED
Palliative Care Intervention in Improving Symptom Control and Quality of Life in Patients With Stage II-IV Non-small Cell Lung Cancer and Their Family CaregiversNCT02243748 · 2015-02-05
COMPLETED
Stereotactic Radiosurgery Followed by Wedge Resection in Treating Patients With Early Stage Peripheral Non-small Cell Lung CancerNCT02250378 · 2014-10-01
WITHDRAWN
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung CancerNCT02178163 · 2014-08-01
ACTIVE_NOT_RECRUITING
Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung CancerNCT01958372 · 2014-08-01
COMPLETED
S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After CrizotinibNCT02134912 · 2014-08-01
TERMINATED
Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung CancerNCT02059889 · 2014-07-01
WITHDRAWN
Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung CancerNCT02145078 · 2014-06-01
TERMINATED
Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or GefitinibNCT01928160 · 2014-06-01
WITHDRAWN
Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung CancerNCT01784640 · 2014-01-31
COMPLETED
Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy RegimensNCT01948141 · 2014-01-30
COMPLETED
Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung CancerNCT01824901 · 2014-01-15
COMPLETED
Impacts of Exercise on Prognostic Biomarkers in Lung Cancer PatientsNCT01999881 · 2013-12-01
COMPLETED
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV InfectionNCT01249443 · 2013-11-01
TERMINATED
Pulmonary Rehabilitation in Improving Lung Function in Patients With Locally Advanced Non-Small Cell Lung Cancer Undergoing ChemoradiationNCT02017925 · 2013-10-01
WITHDRAWN
Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive BiomarkersNCT01935336 · 2013-09-24
COMPLETED
Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung CancerNCT01839955 · 2013-09-01
COMPLETED
INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung CancerNCT01911507 · 2013-08-27
COMPLETED
Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung CancerNCT02126527 · 2013-08-01
WITHDRAWN
PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung CancerNCT01723800 · 2013-07-01
COMPLETED
Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung CancerNCT01781741 · 2013-03-06
COMPLETED
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis TherapyNCT01806675 · 2013-03-04
COMPLETED
Cognitive Behavioral Therapy in Treating Anxiety in Patients With Stage IV Non-Small Cell Lung Cancer and Their CaregiversNCT01729689 · 2012-11-01
COMPLETED
Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung CancerNCT01707823 · 2012-10-01
TERMINATED
IR-guided Ablation (IRGA) Combined With Stereotactic Ablative Radiation (SABR) for Large Lung TumorsNCT01746810 · 2012-07-01
TERMINATED
Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase IINCT01649947 · 2011-12-23
COMPLETED
Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Removed by SurgeryNCT01411098 · 2011-10-01
TERMINATED
Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung CancerNCT01383668 · 2011-06-01
WITHDRAWN
Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By SurgeryNCT01345851 · 2011-03-23
ACTIVE_NOT_RECRUITING
Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the BodyNCT01325753 · 2011-03-01
WITHDRAWN
RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently Completed Treatment With Front-Line ChemotherapyNCT01193868 · 2010-09-01
TERMINATED
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid TumorsNCT01155258 · 2010-06-01
COMPLETED
Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung CancerNCT01026467 · 2010-01-01
COMPLETED
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung CancerNCT00976677 · 2010-01-01
TERMINATED
Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung CancerNCT00986674 · 2009-09-01
COMPLETED
Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerNCT00778167 · 2008-10-01
COMPLETED
AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination ChemotherapyNCT00638937 · 2008-02-01
COMPLETED
Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung CancerNCT00499655 · 2007-11-01
COMPLETED
Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerNCT01557959 · 2007-07-01
COMPLETED
Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung CancerNCT00481078 · 2007-05-01
COMPLETED
Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung CancerNCT00459342 · 2007-03-01
COMPLETED
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerNCT00397384 · 2007-01-01
COMPLETED
E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung CancerNCT00400829 · 2006-11-01
COMPLETED
AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung CancerNCT00410904 · 2006-10-01
COMPLETED
S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung CancerNCT00368992 · 2006-08-01
COMPLETED
Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung CancerNCT00362882 · 2006-07-01
COMPLETED
AZD2171 in Treating Patients With Recurrent Small Cell Lung CancerNCT00245063 · 2006-03-01
COMPLETED
Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerNCT00408460 · 2006-02-01
COMPLETED
Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerNCT00118183 · 2005-07-01
COMPLETED
Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung CancerNCT00118144 · 2005-06-01
COMPLETED
Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung CancerNCT00138203 · 2005-06-01
COMPLETED
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerNCT00101348 · 2005-01-01
COMPLETED
Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerNCT00098540 · 2004-12-01
COMPLETED
Everolimus and Vatalanib in Treating Patients With Advanced Solid TumorsNCT00655655 · 2004-12-01
COMPLETED
Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung CancerNCT00093756 · 2004-09-01
COMPLETED

Common interventions

Leading sponsors

Trial status mix

COMPLETED65
TERMINATED13
WITHDRAWN7
ACTIVE_NOT_RECRUITING2
RECRUITING1

Phase mix

PHASE245
PHASE135
NA14
EARLY_PHASE12
PHASE31
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.